Introduction
Vitamin K-dependent (VKD) proteins undergo γ-glutamyl carboxylation characterized by the conversion of specific glutamic acid (Glu) residues to γ-carboxylated Glu (Gla) (reviewed in ref. 1) . Carboxylation is essential for the functions of VKD proteins, which include coagulation factors like prothrombin (PT) and factors VII, IX, and X that are produced in the liver. VKD proteins are modified in the ER by the γ-glutamyl carboxylase (GGCX), which requires the vitamin K hydroquinone (KH 2 ) cofactor that is oxygenated to vitamin K 2,3-epoxide (KO) during carboxylation. KO is then recycled by VKORC1, a vitamin K oxidoreductase (VKOR) (2, 3) that is evolutionarily conserved (4) . VKORC1 recycles KO to KH 2 in 2 steps, wherein KO is first converted to vitamin K quinone (K) and then to KH 2 (5) . Together, the enzymatic activities of GGCX and VKORC1 form the vitamin K cycle (1) . Warfarin, an anticoagulant used by millions of people, suppresses VKD protein carboxylation by inhibiting VKORC1 (3, 6) .
Deletion of either Ggcx or Vkorc1 in mice resulted in perinatal or postnatal death caused by bleeding defects (7) (8) (9) . However, while the Ggcx -/-mice died during midembryogenesis or immediately after birth (P0) (8) , most of the Vkorc1 -/-mice survived for more than a week following birth (7) , suggesting that another gene might compensate for the absence of Vkorc1. All vertebrates possess a single GGCX but have 2 VKORs. VKORC1, and a paralog named VKORC1-like 1 (VKORC1L1) (2) , are broadly expressed in tissues (9) (10) (11) . While VKORC1 is known to support the carboxylation of VKD proteins (3) , which are also broadly expressed (1) , the role of VKORC1L1 is unknown. VKORC1L1 was shown to reduce KO to K in vitro and to support carboxylation in cells (12, 13 ). Therefore, we tested whether VKORC1L1 has an in vivo role in VKD protein carboxylation.
Results

Carboxylated VKD proteins are present in Vkorc1
-/-mice around birth. PT carboxylation in WT and Vkorc1
-/-mice was monitored to assess the impact of VKORC1 on VKD protein carboxylation. We first established
Vertebrates possess 2 proteins with vitamin K oxidoreductase (VKOR) activity: VKORC1, whose vitamin K reduction supports vitamin K-dependent (VKD) protein carboxylation, and VKORC1-like 1 (VKORC1L1), whose function is unknown. VKD proteins include liver-derived coagulation factors, and hemorrhaging and lethality were previously observed in mice lacking either VKORC1 or the γ-glutamyl carboxylase (GGCX) that modifies VKD proteins. Vkorc1 -/-mice survived longer (1 week) than Ggcx -/-mice (midembryogenesis or birth), and we assessed whether VKORC1L1 could account for this difference. We found that Vkorc1
-/-mice died at birth with severe hemorrhaging, indicating that VKORC1L1 supports carboxylation during the pre-and perinatal periods. Additional studies showed that only VKORC1 sustains hemostasis beyond P7. VKORC1 expression and VKOR activity increased during late embryogenesis and following birth, while VKORC1L1 expression was unchanged. At P0, most (>99%) VKOR activity was due to VKORC1. Prothrombin mRNA, protein, and carboxylation also increased during this period, as did mRNA levels of coagulation factors encoding genes F7, F9, and F10. VKORC1L1 levels in Vkorc1 -/-mouse liver may therefore be insufficient for supporting carboxylation beyond day 7. In support of this conclusion, VKORC1L1 overexpression in liver rescued carboxylation and hemostasis in adult Vkorc1 -/-mice. These findings establish that VKORC1L1 supports VKD protein carboxylation in vivo.
an assay involving immunoprecipitation of carboxylated proteins using rabbit α-Gla antibody, followed by Western blot analysis with appropriate antibodies. The specificity of the α-Gla antibody was validated by testing several VKD proteins that were carboxylated or uncarboxylated (Supplemental Figure 1 , A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.96501DS1). When used in the analysis of plasma samples, we found that carboxylated PT was present in the circulation of WT mice at P0 but was reduced and undetectable in Vkorc1 -/-mice at P0 and P7, respectively ( Figure  1A ). Analysis in liver samples showed that PT carboxylation in Vkorc1 -/-mice was similar to that of WT mice at embryonic day 18.5 (e18.5) but was reduced at P0 and nearly absent at P7 ( Figure 1B) . Liver samples were also monitored for the carboxylation of GGCX, which is a VKD protein (14) . GGCX carboxylation was reduced as early as e18.5 and was undetectable at P7 using the immunoprecipitation assay. In agreement with this and previous studies in cells (14, 15) , we also observed in total liver extracts (i.e., input) that GGCX migrates faster in the absence of Vkorc1 because of its incomplete carboxylation. Therefore, carboxylation is reduced in Vkorc1 -/-mice between the pre-and postnatal period but is not completely blunted, suggesting that a second enzyme supports KO reduction during these periods. ) mice at P0 and P7 was assessed by α-Gla antibody immunoprecipitation, followed by Western blot analysis with α-PT antibody. Input represents 4% of serum sample. (B) PT and GGCX carboxylation in e18.5, P0, and P7 livers from WT and Vkorc1
-/-mice was tested using α-Gla immunoprecipitation and subsequent Western blot analysis with α-PT and α-GGCX antibodies. β-Actin was used as a loading control. Input represents 2% of total protein extract. mice died before 20 days, as previously reported (7), with a median survival age of 9.5 days ( Figure 1D ). In contrast, all Vkorc1 -/-;Vkorc1l1 +/-mice died before 10 days of age, with a median survival age of 1 day. Together, these observations demonstrate that deletion of either 1 or 2 alleles of Vkorc1l1 in a Vkorc1 -/-background causes bleeding defects at a much earlier stage compared with the single inactivation of Vkorc1.
VKORC1L1 supports vitamin K oxidoreduction and carboxylation in the perinatal liver. We therefore determined the consequences of deleting Vkorc1 alone or in combination with 1 or 2 alleles of Vkorc1l1 on perinatal liver VKOR activity and VKD protein carboxylation. A VKOR assay, measuring specifically the conversion of vitamin K epoxide to vitamin K (5), revealed VKORC1L1 activity in the liver. The level was low; Vkorc1 
The percentage of hemorrhages at P0 was calculated for P0 pups whose whole body was recovered.
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be measured due to their early lethality, and e18.5 embryo livers were therefore studied. This analysis revealed a gene dosage effect of VKORC1L1 on PT carboxylation, which was full, partial, or absent in Vkorc1
-/-livers, respectively ( Figure 2C ). GGCX carboxylation showed a similar response. These biochemical studies, thus, showed that VKORC1L1 possesses in vivo VKOR activity that supports carboxylation in the liver during the pre-and perinatal periods. Importantly, the VKOR-C1L1 levels were sufficient for protecting against hemorrhaging at birth and for increasing the survival time of Vkorc1 -/-mice (Table 2 and Figure 1D ). The expression of VKORC1 and VKD coagulation factors increases after birth. VKORC1L1 only allowed survival for 1 week after birth, which we hypothesized might be due to developmental regulation of some components of the vitamin K cycle. We carried out mRNA analysis to test this hypothesis and showed that Vkorc1 but not Vkorc1l1 expression increased robustly in the liver between P0 and P15 ( Figure 3A ). Western analysis indicated the strong induction of VKORC1 but not VKORC1L1 protein ( Figure 3B ). Importantly, VKOR activity significantly increased as liver development progresses ( Figure 3C ). We also analyzed the expression of several mRNAs encoding VKD coagulation factors (F2, F7, F9, and F10) , which all showed increases during the peri-and postnatal periods ( Figure 4A ), and Ggcx expression followed a similar trend -/-was tested using α-Gla immunoprecipitation and subsequent Western blot analysis with α-PT and α-GGCX antibodies. β-Actin was used as a loading control. Input represents 2% of total protein extract. Duplicates represent biological replicates, and the image is representative of 2 independent experiments. (C) PT and GGCX carboxylation in livers from WT,
, and Vkorc1l1 -/-e18.5 embryos were analyzed as in B.
( Figure 4B ). Global VKD protein carboxylation also increased, as assessed by α-Gla Western blot analysis ( Figure 4C ). Finally, both PT protein expression and carboxylation increased in the plasma of WT mice ( Figure 4 , D and E). Collectively, these results indicate that the level of carboxylated coagulation factors significantly increases around birth and that carboxylation is sustained by upregulation of VKORC1, but not VKORC1L1, in the liver. Developmental upregulation of vitamin K cycle components may be conserved in humans, as well, as F2, F10, VKORC1, and GGCX mRNA levels are higher in adult versus fetal livers (Supplemental Figure 3) . The human data are in agreement with the observation that VKD coagulation factor levels are, on average, 75% lower in normal human fetuses compared with adults (16) .
Increasing liver VKORC1L1 levels in Vkorc1 -/-mice rescues VKD carboxylation. Altogether, the results presented above suggest that, after 1 week of age, VKORC1L1 expression in the absence of VKORC1 is insufficient in supporting the increased demand for VKD protein carboxylation, causing hemorrhaging and death. This hypothesis was tested by elevating VKORC1L1 levels in the livers of Vkorc1 -/-mice and determining the consequence on hemostasis, carboxylation, and survival. We generated APOE-Vkorc1l1 transgenic mice in which the liver-specific regulatory sequences of the human APOE gene were used to express a FLAG-tagged version of VKORC1L1 specifically in hepatocytes ( Figure 5A ). Two of several independent transgenic lines were selected (APOE-Vkorc1l1 73 and APOE-Vkorc1l1
70
), which had a 2-fold difference in VKORC1L1-FLAG expression ( Figure 5B ). Western analysis showed liver-specific expression ( Figure 5C ), and quantitative PCR (qPCR) revealed ~20-fold higher expression of Vkorc1l1 than Vkorc1 mRNA (Figure 5D) . However, quantification analysis by Western blot indicated that the level of VKORC1L1-FLAG protein reached was ~25 times lower (i.e., <4%) than the level of endogenous VKORC1 in WT animals ( Figure 5E and Supplemental Figure 4) . APOE-Vkorc1l1 73 transgenic mice were then bred to Vkorc1 +/-mice to generate Vkorc1 +/-; APOE-Vkorc1l1 73 animals, which were subsequently backcrossed to Vkorc1 +/-mice. Progeny from the second cross were then analyzed at P5, a time at which all of the possible genotypes were observed at the expected frequency (Table 3) . Increased VKORC1L1 expression was sufficient to support production of active PT; while PT time assessed as the international normalized ratio (INR) was markedly increased in Vkorc1 -/-pups, as expected, INR values in Vkorc1 -/-; APOE-Vkorc1l1 73 were comparable with WT mice ( Figure 6A ). Accordingly, global carboxylation in liver was completely blunted in Vkorc1 -/-P5 pups but was rescued to nearly WT levels in Vkorc1 -/-; APOE-Vkorc1l1 73 mice ( Figure 6B ). In addition, PT and GGCX carboxylation in mouse liver were absent in P5 Vkorc1 -/-mice but comparable with WT in Vkorc1 and Vkorc1l1 mRNA expression in C57BL/6J livers at e14.5, e16.5, e18.5, P0, P7, and P15 were measured by quantitative PCR (qPCR) and normalized to Actb (n = 3; mean ± SEM). Copy number was quantified using plasmid DNA containing either Vkorc1 or Vkorc1l1 cDNA as a standard. (B) Protein expression in liver at e16.5, e18.5, P0, P7, and P15 was analyzed by Western blot using antibodies against VKORC1, VKORC1L1, GGCX, or β-actin. Quantification shows arbitrary densitometry units of VKORC1 signal relative to VKORC1L1. (C) VKOR activity in C57BL/6J livers at e16.5, e18.5, P0, P7, and P15 was measured (n = 4; mean ± SEM; 1-way ANOVA tests followed by Bonferroni's multiple comparisons test; **P < 0.01; ***P < 0.001).
Increasing liver VKORC1L1 levels supports survival of Vkorc1
-/-mice to adulthood. We next investigated whether elevated VKORC1L1 levels in liver rescue the hemostatic defects and lethality associated with VKORC1 deficiency beyond 1 week of age. In contrast to Vkorc1 -/-mice that all died before 20 days, the Vkorc1 -/-; APOE-Vkorc1l1 73 mice reached weaning with the expected Mendelian frequency (12.5%), and most survived past 6 months of age without any noticeable phenotype (Table 3 and Figure 6E ). Both APOE-Vkorc1l1 transgenic lines tested rescued the postnatal lethality of VKORC1 deficiency (Table 3  and Supplemental Table 1 ). Finally, INRs were within the normal range in 4-month-old adult Vkorc1 -/-; APOE-Vkorc1l1 73 mice ( Figure 6F ). Therefore, VKORC1L1 expressed at sufficient levels prevents bleeding and lethality in adult mice, even in the absence of VKORC1.
Discussion
In summary, our results establish for the first time to our knowledge that VKORC1L1 supports VKD protein carboxylation in vivo. The study focused on VKORC1L1 function in liver because of the difference in timing of hemorrhaging and lethality in Vkorc1 -/-and Ggcx -/-mice (7, 8) . While VKORC1L1 expression and activity are much lower than that of VKORC1 in liver, it may have a more dominant role in some extrahepatic tissues. VKORC1L1 and VKORC1 are both broadly expressed, as are VKD proteins that have multiple functions besides hemostasis, and Vkorc1l1 mRNA levels are higher than that of Vkorc1 in some tissues (e.g., brain and testes) (10, 11) . It should be noted that the results do not rule out alternative roles for VKORC1L1 -for example, in oxidative stress, as previously suggested (12) . Importantly, our data also revealed that blood coagulation is a developmentally regulated process. We found that VKD clotting factors and the machinery responsible for their activation both increased periand postnatally. These results are of interest regarding newborn hemorrhaging, which has been attributed solely to vitamin K deficiency ameliorated by supplementation at birth. Indeed, our data suggest that, in some cases, the hemorrhagic response could also be due to low VKORC1 activity in the liver. These (A), and Ggcx (B) were measured by qPCR in C57BL/6J livers at e14.5, e16.5, e18.5, P0, P7, and P15 and normalized to Actb (n = 3; mean ± SEM). (C) Global VKD protein carboxylation in livers from e16.5, e18.5, P0, P7, and P15 C57BL/6J mice was analyzed by Western blot using α-GLA antibody. GADPH was used as a loading control. (D) PT protein and carboxylation in plasma from e16.5, e18.5, P0, P7, and P15 C57BL/6J mice were monitored by immunoprecipitation with α-PT antibody, followed by Western blot analysis with α-Gla or α-PT antibodies. Input represents 4% of serum sample. Duplicates represent biological replicates, and the image is representative of 2 independent experiments. (E) Densitometry values from D were normalized to the e16.5 sample.
findings also raise questions about the role of carboxylated proteins during embryogenesis. Of interest, for example, is whether upregulation of VKD clotting factors is important because the neonate/adult is more exposed to injury than the fetus, and whether other VKD proteins known to be expressed in adult liver (e.g., GAS6) are also developmentally regulated.
Interestingly, all of the Vkorc1 -/-;Vkorc1l1 -/-mice survived until birth, while previous studies showed that about half of Ggcx -/-mice died mid-embryogenesis (8) . GGCX function requires KH 2 , and the 73 mice at 4 weeks of age was assessed by qPCR and normalized to Actb (n = 3; mean ± SEM). Copy number was quantified using plasmid DNA containing either Vkorc1 or Vkorc1l1 cDNA as a standard. (E) VKORC1 and VKORC1L1-FLAG protein levels in liver from WT and APOE-Vkorc1l1 73 mice were measured by Western blot using α-VKORC1 and α-FLAG antibodies. VKORC1-FLAG-and VKORC1L1-FLAG-transfected HEK293 cells were used as a standard and β-actin as a loading control (n = 2; mean ± SEM; Supplemental Figure 4 ). results therefore suggest that an additional reductase supports carboxylation during embryogenesis. A quinone reductase that reduces K to KH 2 is present in adult mouse liver (7). The carboxylase converts KH 2 to KO that the quinone reductase cannot recycle, and vitamin K levels from maternal transfer are low (17) . Consequently, a quinone reductase could only support a limited amount of VKD protein carboxylation. In this regard, it is worth noting that many VKD clotting factors also function in signaling, activating protease-activated receptors (PARs) thought to be important to embryonic development (18) . PT, factor X, and PAR1 deficiency in mice all result in approximately half of the embryos dying midgestation (18) (19) (20) , which may reflect the role of these VKD proteases in signaling. The amounts of carboxylated protein required for signaling would be substantially less then that needed for clotting, and so a quinone reductase could be functionally significant. We note that quinone reductase activity in adult liver only supports blood clotting in the context of administration of high doses of vitamin K (7, 21), which were not used here; therefore, the presence of the quinone reductase in embryonic liver should not affect blood coagulation and the conclusion of the current study. 
Methods
Animal models. Vkorc1
+/-and Vkorc1l1 +/-mice, generated in our laboratory, were maintained on a C57BL/6J background (backcrossed for more than 10 generations with C57BL/6J mice from the Jackson Laboratory) and described previously (9) were crossed to generate Vkorc1 +/-;Vkorc1l1 +/-mice, which were further intercrossed to generate e16.5, e18.5, P0, P7, and P15 mice of the various studied genotypes. Mouse Vkorc1l1 cDNA was cloned in the p3XFLAG-CMV-14 vector, and the SpeI site was then removed by mutagenesis. APOE-Vkorc1l1 transgene was generated by cloning the 3XFLAG-tagged version of mouse Vkorc1l1 cDNA into the pLIV.7 plasmid, which contains the liver-specific human APOE promoter and regulatory sequences (22) (see Supplemental Table 2 for a list of the oligos and restriction sites used in the cloning). The APOE-Vkorc1l1 transgenic construct was excised from the plasmid using SpeI and SacII unique restriction sites, purified, and microinjected into mouse fertilized oocytes from F2 (C3H/HeNHs × C57BL/6J). Transgenic and mutant mice were identified by specific PCR (Supplemental Table 2 ;APOE-Vkorc1l1 mice (genetic background: ~87.5% C57BL/6J, ~12.5% C3H/HeNHs). Both males and females were used in this study.
Plasmid constructs. GGCX-FLAG and PT-FLAG plasmids were generated by PCR amplification and cloning in the HindIII and BamHI sites of p3XFLAG-CMV-14 vector. PRRG2-FLAG plasmid was generated by PCR amplification and cloning in the EcoRI and KpnI sites of p3XFLAG-CMV-14 vector. GAS6-Myc and MGP-Myc were generated by PCR amplification and cloning in the EcoRI and XbaI sites of pcDNA3.1/myc-His B. Sequences of the primers used for cloning are included in Supplemental Table 2 .
Generation of rabbit polyclonal α-Gla antibodies. The α-Gla antibody was developed in collaboration with Covance Inc. Rabbits were immunized with the H2N-G(Gla)G(dPEG4)G(Gla)G(dPEG4)C-OH synthetic peptide, and rabbit immunoglobulins were affinity purified against H2N-G(Gla)G and depleted against GEGGE peptides. The specificity of the antibodies toward carboxylated residues was tested by immunoprecipitation and Western blot (Supplemental Figure 1, A and B) .
Immunoprecipitation and Western blot assays. Livers were homogenized in lysis buffer containing: 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1 mM EGTA, 2.5 mM NaPyrophosphate, 1 mM β-glycerophosphate, 10 mM NaF, 1% Triton, 1 mM PMSF, and protease inhibitors (EDTA-free protease inhibitor cocktail tablets, Roche Diagnostics). For α-Gla immunoprecipitation, 200 μg of liver extracts from each condition were incubated overnight with rotation at 4°C with 12 μg of rabbit α-Gla antibodies followed by 3 hours incubation with 40 μl of Protein A-Agarose beads (Roche Diagnostics). Immunoprecipitated proteins were washed 4 times with lysis buffer, resuspended in loading buffer, and heated at 70°C for 10 minutes before being resolved by SDS-PAGE on 7.5% polyacrylamide Tris-Glycine gels. Proteins were detected in the immunoprecipitated and input (4%) fractions by Western blot following standard procedures using sheep α-PT (Thermo Fisher Scientific, PA1-43062), rabbit α-GGCX (Proteintech, 16209-1-AP), and mouse α-β-actin (MilliporeSigma, A5441) antibodies.
Mouse blood was collected using heparinized capillaries and EDTA-treated tubes, and cells were removed from plasma by centrifuging at 800 g for 5 minutes at room temperature. For α-PT immunoprecipitation, 2 μl of plasma was diluted in 500 μl of lysis buffer for each condition. Samples were precleared using 40 μl of protein G-Agarose beads (Roche Diagnostics) for 2 hours at 4°C before adding 14 μg of α-PT antibodies and incubating at 4°C overnight with rotation. For α-Gla immunoprecipitation, 2 μl of plasma was diluted in 500 μl of lysis buffer, and samples were precleared using 40 μl of protein A-Agarose beads for 2 hours at 4°C before adding 14 μg of α-Gla antibodies. Immunoprecipitated proteins were washed 4 times with lysis buffer, resuspended in loading buffer, and heated at 70°C for 10 minutes before being resolved on SDS-PAGE and detected by Western blot using rabbit α-Gla and sheep α-PT antibodies.
HEK293 cells (ATCC), cultured in EMEM supplemented with 10% heat-inactivated FBS, were transfected using Lipofectamine 2000 per manufacturer's instructions (Invitrogen) with plasmids containing either GGCX-FLAG, PT-FLAG, PRRG2-FLAG, GAS6-Myc, or MGP-Myc in presence of warfarin (Santa Cruz Biotechnology Inc., 50 μM) or vitamin K 1 (MilliporeSigma, 22 μM). Two days after transfection, cells were harvested in lysis buffer, and 200 μg of each condition was used for α-Gla immunoprecipitation as described above. GGCX-FLAG, PT-FLAG, and PRRG2-FLAG were detected using mouse α-FLAG M2 antibodies (MilliporeSigma, F1804). GAS6-Myc and MGP-Myc were detected using mouse α-Myc antibodies (Cell Signaling Technologies, 2276).
